#USA #Raleigh #RedHill Biopharma #Talicia #H. pylori

RedHill Biopharma's Initiative for H. Pylori Education

RedHill Biopharma Ltd. is making significant strides in the medical education sector by sponsoring a new two-part Continuing Medical Education (CME) program focused on H. Pylori, a bacterial infection impacting a substantial portion of the global population. This initiative is developed in collaboration with Medscape and aims to enhance clinical knowledge and improve patient outcomes for healthcare professionals dealing with H. Pylori infections.

The Importance of H. Pylori

H. Pylori is recognized as a Group 1 carcinogen by the World Health Organization (WHO). It is the leading risk factor for gastric cancer, responsible for 70% to 90% of cases. Moreover, this bacterium is linked to peptic ulcer disease, a condition affecting millions worldwide. Nearly half of the global population is estimated to be infected with H. Pylori, highlighting the urgent need for effective management and treatment strategies, which represent an extensive and lucrative market opportunity.

CME Program Overview

The CME program will consist of two parts:

Part 1: Let's Get Social About H. Pylori Management

Scheduled for May 6, 2025, this online event will feature renowned experts William Chey, MD, Vivian Asamoah, MD, and Shailja Shah, MD, MPH. The live panel discussion will address crucial topics including antibiotic resistance, guideline-driven therapies, and patient adherence in managing H. Pylori infections. This event will provide participants with insights into recent developments and best practices in H. Pylori management from the comfort of their own locations. After the live presentation, the session will be available for on-demand access on multiple social media platforms, catering to healthcare professionals who cannot attend the live session.

Part 2: Expert Roundtable on H. Pylori Diagnosis and Treatment

The second part of the CME program will take place in June 2025 (date to be confirmed). This engaging roundtable will allow participants to dive deeper into the challenges surrounding H. Pylori diagnosis and treatment. Clinicians will have the opportunity to engage in case-based discussions and interactive Q&A sessions, facilitating a better understanding of current guidelines and optimizing patient care pathways.

RedHill Biopharma's Commitment

RedHill Biopharma, known for its innovative therapies, emphasizes the significance of early and effective treatment of H. Pylori infections. As antibiotic resistance becomes a growing concern, the company aims to ensure that healthcare providers are armed with the most current knowledge and tools to combat this prevalent infection. Kel Sheldon, PhD, BCMAS, the Director of Medical Affairs at RedHill, stated, "We are proud to support this CME educational program, aiming to meet the critical need for healthcare professional education regarding H. Pylori treatment options."

The company's leading product for H. Pylori management, Talicia®, is distinguished as the only FDA-approved all-in-one and low-dose rifabutin-based therapy designed to combat antibiotic resistance, marking it as a preferred choice among U.S. gastroenterologists.

Future Directions

In addition to the educational initiatives, RedHill Biopharma will be present at this year’s Digestive Diseases Week (DDW) in San Diego at booth 5312. The company is also exploring global market opportunities for Talicia, having recently launched it in the UAE and planning to seek marketing authorization in the United Kingdom.

In summary, RedHill Biopharma's commitment to advancing medical education around H. Pylori through support for the CME program signifies its dedication to improving patient outcomes and addressing the complexities of H. Pylori diagnosis and treatment. With a focus on both current and future healthcare challenges, RedHill continues to play a pivotal role in the management of this significant health issue.